Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies


#233909

N/A

GBI Research

$ 4995

In Stock

GBI Research, the leading business intelligence provider, has released its latest research: ‘Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies ’, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. 

It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. 

The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes:

  • A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

  • Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Colorectal Cancer
2.2 Symptoms
2.3 Epidemiology
2.4 Pathophysiology
2.4.1 Histology
2.4.2 Genetic Basis
2.4.3 Etiology
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium Enema
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Targeted Therapies
2.7.4 Resistance to Pharmacological Therapies
2.7.5 Treatment Guidelines

3 Marketed Products
3.1 Key Marketed Products
3.1.1 Immunotherapies
3.1.2 Targeted Therapies
3.2 Hyperthermic Intraperitoneal Chemotherapy
3.3 Heat Map for Marketed Products

4 Pipeline Analysis
4.1 Overall Pipeline
4.1.1 Pipeline Analysis by Molecule Type
4.1.2 Pipeline Analysis by Mechanism of Action
4.2 Clinical Trials
4.2.1 Failure Rate
4.2.2 Clinical Trial Size
4.2.3 Duration
4.3 Promising Drug Candidates in Pipeline
4.3.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical
4.3.2 Cyramza – ramucirumab – Eli Lilly and Company
4.3.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical
4.3.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals
4.3.5 MelCancerVac – DanDrit Biotech
4.3.6 Xilonix – XBiotech
4.3.7 Nintedanib – Boehringer Ingelheim

5 Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 India
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 China
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers

6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Major Licensing Deals
6.2 Co-development Agreements
6.2.1 Major Co-development Agreements

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2020
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 India
7.2.4 China
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer
Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013
Table 2 Surgical Options for Colorectal Cancer
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2013
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
Table 9 Colorectal Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 10 Colorectal Cancer Therapeutics, Australia, Forecast Data, 2013–2020
Table 11 Colorectal Cancer Therapeutics, India, Forecast Data, 2013–2020
Table 12 Colorectal Cancer Therapeutics, China, Forecast Data, 2013–2020
Table 13 Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013–2020

Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III)
Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV)
Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products)
Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013
Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013
Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013
Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013
Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2013
Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013
Figure 10: Colorectal Cancer Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000) ,2013–2020
Figure 11: Colorectal Cancer Therapeutics, Asia-Pacific, Market Size ($bn), 2013–2020
Figure 12: Colorectal Cancer Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 13: Colorectal Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 14: Colorectal Cancer Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 15: Colorectal Cancer Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Colorectal Cancer Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 17: Colorectal Cancer Therapeutics, India, Market Size ($m), 2013–2020
Figure 18: Colorectal Cancer Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 19: Colorectal Cancer Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 20: Colorectal Cancer Therapeutics, China, Market Size ($m), 2013–2020
Figure 21: Colorectal Cancer Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 22: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 23: Colorectal Cancer Therapeutics, Japan, Market Size, 2013–2020
Figure 24: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006–2014
Figure 25: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006–2014
Figure 26: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006–2014
Figure 27: GBI Research Market Forecasting Model